<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006968</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068349</org_study_id>
    <secondary_id>UCLA-0001032</secondary_id>
    <secondary_id>SUPERGEN-UCLA-000103201</secondary_id>
    <secondary_id>NCI-G00-1879</secondary_id>
    <nct_id>NCT00006968</nct_id>
  </id_info>
  <brief_title>Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer</brief_title>
  <official_title>Non-Myeloablative Chemotherapy Followed By Related Allogeneic Stem Cell Rescue In Patients With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with donor peripheral stem cell&#xD;
      transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of pentostatin followed by peripheral&#xD;
      stem cell transplantation in treating patients who have advanced kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the duration and efficiency of hematopoietic and immunologic engraftment in&#xD;
           patients with advanced renal cell carcinoma treated with pentostatin followed by related&#xD;
           allogeneic stem cell transplantation.&#xD;
&#xD;
        -  Determine the hematologic and non-hematologic toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the incidence and severity of graft-versus-host disease in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of pentostatin.&#xD;
&#xD;
        -  Phase I: Patients receive pentostatin IV on days -7, -5, and -3 followed by allogeneic&#xD;
           stem cell transplantation on day 0. Beginning on day 1, patients receive filgrastim&#xD;
           (G-CSF) IV over 1 hour or subcutaneously daily until blood counts recover. As&#xD;
           graft-versus-host disease prophylaxis, patients receive cyclosporine IV continuously&#xD;
           until stem cell engraftment and then orally with gradual tapering.&#xD;
&#xD;
      Cohorts of 3 to 6 patients receive escalating doses of pentostatin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive treatment as in phase I at the MTD for pentostatin. Patients&#xD;
           are followed weekly for 60 days and then monthly for 10 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients (12 per phase) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">4</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentostatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced renal cell cancer&#xD;
&#xD;
          -  No bone metastases&#xD;
&#xD;
          -  No CNS disease&#xD;
&#xD;
          -  Must have an allogeneic donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  3 to 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Complete blood count normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 4 times ULN&#xD;
&#xD;
          -  No evidence of portal hypertension&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No uncontrolled hypercalcemia&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class 3 or 4 heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 40% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No severe functional neurological impairment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No more than 1 prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 6 months of prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 1 year since prior steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary J. Schiller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>June 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2003</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

